Coave Therapeutics Funding: $39M Raised, Series B (2021)
Coave Therapeutics is a Biotech company based in Paris, France. It has raised $39M in total funding. Latest round: Series B.
Coave Therapeutics funding overview
Coave Therapeutics is a Biotech company based in Paris, France. Coave Therapeutics has raised $39M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in July 2021. The round record for Coave Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures and 4 others. 10 distinct backers are named across the disclosed rounds.
Coave Therapeutics at a glance
Total raised
$39M
Latest round
Series B
Latest round date
July 2021
Industry
Biotech
Headquarters
Paris, France
Notable investors
Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest
Frequently asked about Coave Therapeutics funding
How much has Coave Therapeutics raised?
Coave Therapeutics has raised $39M in total disclosed funding across the rounds on record.
Who has invested in Coave Therapeutics?
Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures are named among the investors backing Coave Therapeutics.
What was the latest Coave Therapeutics funding round?
The most recent disclosed round is a Series B, announced in July 2021.
Where is Coave Therapeutics based?
Coave Therapeutics is based in Paris, France.
What sector does Coave Therapeutics operate in?
Coave Therapeutics is tracked under Biotech from Paris, France, with $39M in disclosed funding.
When did Coave Therapeutics last raise?
The last disclosed Coave Therapeutics round closed in July 2021 at Series B.
Coave Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Paris below to benchmark round size and investor mix.
